No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
No Data
Maxim Group Maintains Rani Therapeutics(RANI.US) With Buy Rating, Maintains Target Price $15
H.C. Wainwright Maintains Rani Therapeutics(RANI.US) With Buy Rating, Maintains Target Price $13
BTIG Maintains Rani Therapeutics(RANI.US) With Buy Rating, Maintains Target Price $14
Express News | Rani Therapeutics: Co, Progen to Share Responsibilities for Rt-114, Including 50/50 Cost & Revenue Share
Express News | Rani & Progen Partnership With No Upfront Payment
Express News | Rani Therapeutics & Progen Co-Develop Rt-114